Main Line Endoscopy Centers are now offering a first-of-its-kind, AI-derived precision medicine test that helps in predicting the risk of progression to cancer in patients with Barrett’s esophagus (BE).

Barrett’s esophagus is a medical condition that causes the esophageal tissue lining to change and resemble the lining of the intestine. Symptoms can include severe heartburn, difficulty swallowing and, in some cases, chest pain. Chronic gastroesophageal reflux disease (GERD) is a key risk factor and can increase a patient’s likelihood of developing esophageal cancer over time.

Performed on routine esophageal biopsies, the test analyzes a patient’s tissue to determine their five-year probability of progression to high-grade dysplasia or cancer. The results integrate with clinical guidelines and can be used alongside traditional dysplasia-based grading to enhance patient care.

Early detection plays a vital role in preventing the progression of esophageal cancer and improving outcomes for patients with Barret’s esophagus. The results produced by this test increase the ability to tailor treatment depending on each patient’s individualized risk. “Barrett’s esophagus can progress differently from patient to patient. This cutting-edge technology offers us a clearer picture of what treatment plans can be most impactful for each individual while saving lives along the way,” William Huntington, DO shared.

If you are a patient with Barrett’s esophagus or are experiencing symptoms of the condition and would like to learn more about this test, please schedule an appointment with one of our physicians. Additionally, you can learn more about this condition here.